Story
Scribe Therapeutics Files for Nasdaq Initial Public Offering
Scribe Therapeutics, a biotechnology company, has officially filed for an initial public offering (IPO) with U.S. regulators. The company intends to list its common stock on the Nasdaq Global Market under the proposed ticker symbol 'SCTX'.
Filing Details
According to the registration statement, the company has not yet determined the number of shares to be offered or the prospective price range for the IPO. The filing included placeholder values for these amounts, which is a standard procedure in the early stages of the IPO process.
Scribe Therapeutics noted that there is currently no public market for its common stock. The completion of the offering is contingent upon the company meeting all of Nasdaq's listing standards.
Underwriters and Market Context
AdA consortium of investment banks is set to manage the offering. The underwriters listed in the filing include:
- Leerink Partners
- Goldman Sachs & Co. LLC
- Guggenheim Securities
- Wells Fargo Securities
This move signals Scribe's intent to raise capital from public investors to fund its operations and research. The filing will be closely watched by market participants as an indicator of investor appetite for new listings in the biotechnology sector.